ArticleScientific reports2025
Htra4 promotes vascular endothelial cell injury and is associated with the early-onset of preeclampsia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trophoblast Function in Preeclampsia: Decoding the Mechanistic Roles of Coding and Non-Coding Genes.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Preeclampsia (PE) is a pregnancy-specific disorder characterized by multi-system involvement, leading to increased perinatal morbidity and mortality as well as long-term cardiovascular damage in both mother and fetus. This study aimed to investigate the alterations and potential role of high temperature requirement factor A4 (Htra4) in early-onset PE. We conducted a comparative analysis of the baseline data between patients with early-onset PE and normal controls, as well as analyzed the correlation of Htra4 levels in the peripheral blood with pregnancy outcomes. Additionally, we investigated the impact of recombinant protein Htra4 on human umbilical vein endothelial cells (HUVECs). Patients with early-onset PE patients exhibited cardiac, hepatic, and renal impairment, as well as elevated levels of Htra4 in peripheral blood but not in umbilical cord blood. Further correlation analysis reveals a significant association between peripheral blood Htra4 levels and adverse pregnancy outcomes in patients with early-onset PE, particularly a strong correlation between maternal blood Htra4 levels and systolic and diastolic blood pressure, suggesting that Htra4 may be associated with impaired vascular function. Histopathological examination revealed inadequate trophoblast cell invasion in the decidua of early-onset PE patients, along with unsuccessful uterine artery remodeling. Additionally, the spiral arterial lumen in the decidua exhibited narrower and irregularly shaped remodeling. Immunofluorescence localization demonstrated the expression of Htra4 in trophoblasts of villous as well as extra-villous lineages. We observed intensified Htra4 staining in the placenta and decidua tissues of patients with early-onset PE. In combination with the pathological alterations of decidual vessels, it is hypothesized that Htra4 might be related to the dysfunction of endothelial cells. Subsequent research indicated that Htra4 induce the onset of oxidative stress, and inflammatory response in HUVECs, suggesting a potential association between the elevated Htra4 levels and vascular endothelial injury in patients with early-onset PE. This study identified a correlation between Htra4 and adverse pregnancy outcomes in patients with early-onset PE, potentially leading to vascular endothelial injury through elevated levels of Htra4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.